STOCK TITAN

Elite Pharmaceuticals Receives FDA Approval for Generic Sabril(R)

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Rhea-AI Summary

Elite Pharmaceuticals has received FDA approval for its generic version of Sabril (Vigabatrin USP) 500 mg powder for solution. This antiepileptic drug is indicated for refractory complex partial seizures, targeting patients with inadequate responses to alternative treatments. Lannett Company holds the exclusive marketing rights in the U.S. and territories, while Elite will manufacture and package the product. The collaboration entails shared profits from product net sales, enhancing Elite's market position in the specialty pharmaceutical sector.

Positive
  • FDA approval for generic Vigabatrin enhances Elite's product portfolio.
  • Collaboration with Lannett Company ensures exclusive marketing rights and potential revenue sharing.
Negative
  • None.

NORTHVALE, NJ / ACCESSWIRE / June 29, 2022 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing niche generic products, today announced that it received approval from the US Food and Drug Administration (FDA) for an Abbreviated New Drug Application (ANDA) for a generic version of Sabril® (Vigabatrin USP) 500 mg powder for solution packet.

Vigabatrin is an antiepileptic drug indicated for refractory complex partial seizures and used as an adjunctive therapy in patients who have inadequately responded to several alternative treatments. Lannett Company, Inc. has an exclusive license to market and distribute the product in the U.S. and territories. Elite will exclusively manufacture and package the product for sale for an agreed-upon transfer price. The companies will share in product net profits.

About Lannett Company, Inc.

Lannett Company, founded in 1942, develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of medical indications. For more information, visit the company's website at www.lannett.com.

About Elite Pharmaceuticals, Inc.

Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops niche generic products. Elite specializes in developing and manufacturing oral, controlled-release drug products. Elite owns multiple generic products which have been licensed to Lannett Company, Prasco, LLC, Epic Pharma, LLC, and TAGI Pharma. Elite operates a cGMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ. For more information, visit www.elitepharma.com.

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, those related to the effects, if any, on future results, performance or other expectations that may have some correlation to the subject matter of this press release. Readers are cautioned that such forward-looking statements involve, without limitation, risks, uncertainties, and other factors not under the control of Elite, which may cause actual results, performance or achievements of Elite to be materially different from the results, performance or other expectations that may be implied by these forward-looking statements. These forward-looking statements may include statements regarding the expected timing of approval, if at all, of products by the FDA, and the actions the FDA may require of Elite in order to obtain such approvals. These forward-looking statements are not guarantees of future action or performance. These risks and other factors are discussed, without limitation, in Elite's filings with the Securities and Exchange Commission, including its reports on forms 10-K, 10-Q, and 8-K. Elite is under no obligation to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:
Elite Pharmaceuticals, Inc.
Dianne Will, Investor Relations
518-398-6222
Dianne@elitepharma.com

SOURCE: Elite Pharmaceuticals, Inc.



View source version on accesswire.com:
https://www.accesswire.com/706809/Elite-Pharmaceuticals-Receives-FDA-Approval-for-Generic-SabrilR

FAQ

What product did Elite Pharmaceuticals receive FDA approval for?

Elite Pharmaceuticals received FDA approval for a generic version of Sabril (Vigabatrin USP) 500 mg powder for solution.

What is the indication for Vigabatrin?

Vigabatrin is indicated for refractory complex partial seizures in patients who have not adequately responded to alternative treatments.

Who is responsible for marketing the approved product?

Lannett Company has the exclusive license to market and distribute the generic version of Sabril in the U.S. and territories.

What role does Elite Pharmaceuticals play in the production of Vigabatrin?

Elite Pharmaceuticals will exclusively manufacture and package the generic Vigabatrin for sale under an agreed-upon transfer price.

What potential benefits does the FDA approval bring to Elite Pharmaceuticals?

The FDA approval allows Elite Pharmaceuticals to expand its product offerings and benefit from profit sharing with Lannett Company.

ELITE PHARMS INC

OTC:ELTP

ELTP Rankings

ELTP Latest News

ELTP Stock Data

640.96M
833.24M
22%
2.16%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States of America
Northvale